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Missense mutations in leucine-rich repeat kinase 2 (LRRK2) are pathogenic for familial Parkinson’s disease. However, it is un-
known whether levels of LRRK2 protein in the brain are altered in patients with LRRK2-associated Parkinson’s disease. Because
LRRK2 mutations are relatively rare, accounting for approximately 1% of all Parkinson’s disease, we accessioned cases from ﬁve
international brain banks to investigate levels of the LRRK2 protein, and other genetically associated Parkinson’s disease proteins.
Brain tissue was obtained from 17 LRRK2 mutation carriers (12 with the G2019S mutation and ﬁve with the I2020T mutation)
and assayed by immunoblot. Compared to matched controls and idiopathic Parkinson’s disease cases, we found levels of LRRK2
protein were reduced in the LRRK2 mutation cases. We also measured a decrease in two other proteins genetically implicated in
Parkinson’s disease, the core retromer component, vacuolar protein sorting associated protein 35 (VPS35), and the lysosomal
hydrolase, glucocerebrosidase (GBA). Moreover, the classical retromer cargo protein, cation-independent mannose-6-phosphate
receptor (MPR300, encoded by IGF2R), was also reduced in the LRRK2 mutation cohort and protein levels of the receptor were
correlated to levels of LRRK2. These results provide new data on LRRK2 protein expression in brain tissue from LRRK2 mutation
carriers and support a relationship between LRRK2 and retromer dysfunction in LRRK2-associated Parkinson’s disease brain.
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Introduction
The leucine-rich repeat kinase 2 (LRRK2) protein has
emerged as an exciting potential target for the therapeutic
treatment of Parkinson’s disease. At least six missense
mutations in the LRRK2 gene have been identiﬁed that
predispose to an increased risk of inherited Parkinson’s
disease (Cookson, 2010). When measured using either
autophosphorylation of LRRK2 (Sheng et al., 2012), or
phosphorylation of downstream Rab protein substrates
(Steger et al., 2016), all pathogenic mutations increase the
kinase activity of LRRK2, at least in animal and cell culture
models. Consequently, there has been much investment in
the development and characterization of small molecule
inhibitors of LRRK2 activity, and some early studies in
preclinical models are suggestive of a protective effect of
such compounds (Atashrazm and Dzamko, 2016). Efforts
to further develop and translate LRRK2 therapeutics are
ongoing and an important translational step is to build
an understanding of LRRK2 expression and function in
pathologically relevant human biospecimens.
We have previously comprehensively measured LRRK2
levels in post-mortem brain tissue from cases with idio-
pathic Parkinson’s disease, and preclinical cases with
Lewy body pathology restricted to the olfactory bulb, sym-
pathetic ganglia, medulla oblongata, and/or locus coeruleus
(Dzamko et al., 2017). Compared to controls, we found an
early upregulation of LRRK2 protein in the cases with re-
stricted Lewy bodies, that was followed by a disease dur-
ation-dependent decrease in LRRK2 levels back to the same
level as controls. However, little is known about LRRK2
expression in cases with LRRK2 mutations for at least two
reasons. The ﬁrst is that characterized post-mortem muta-
tion cases are very rare, and second, there has been much
difﬁculty in ascertaining antibodies suitable for measuring
LRRK2 in formalin-ﬁxed brain tissue (Davies et al., 2013;
Dzamko et al., 2017). In the current study we have ob-
tained 17 LRRK2 mutation cases and compared levels of
LRRK2 to idiopathic Parkinson’s disease and also controls
by immunoblot using our established methods. Twelve of
the LRRK2 mutation cases contained the G2019S muta-
tion, the most common LRRK2 mutation that may account
for up to 1% of all Parkinson’s disease (Healy et al., 2008).
The remaining ﬁve cases contained the neighbouring
I2020T mutation, found in the Sagamihara region in
Japan (Hasegawa et al., 2009). The cases were as expected
for these two mutations (Kalia et al., 2015), with the
G2019S cases with Parkinson’s disease having Lewy path-
ology and non-motor features by end-stage, while those
Parkinson’s disease cases with the I2020T mutation were
without non-motor features and Lewy bodies.
Although LRRK2 mutations confer enhanced risk of de-
veloping Parkinson’s disease, it is generally regarded that
these mutations are not fully penetrant, and thus other
genetic and/or environmental factors likely contribute to
disease conversion (Trinh et al., 2014; Marder et al.,
2015). Thus, we measured the levels of LRRK2, and two
other key proteins that are genetically implicated in
Parkinson’s disease, vacuolar protein sorting associated
protein 35 (VPS35) and glucocerebrosidase (GBA), to de-
termine whether these proteins were dysregulated in the
LRRK2 mutation cases. VPS35 is a component of the retro-
mer complex, which is involved in retrograde endosomal to
trans-Golgi trafﬁcking (Trousdale and Kim, 2015). Like
LRRK2, missense mutations in VPS35 are associated with
dominantly inherited Parkinson’s disease (Zimprich et al.,
2011; Struhal et al., 2014), and studies in Drosophila have
functionally linked LRRK2 and VPS35 in the same trafﬁck-
ing pathways that may mediate neurodegeneration
(MacLeod et al., 2013). GBA is a lysosomal glucosidase
and heterozygous missense mutations in GBA are another
genetic risk factor for Parkinson’s disease (Brockmann and
Berg, 2014). Both GBA and LRRK2 have been implicated
in dysfunction of the lysosomal-autophagy pathway in
Parkinson’s disease (Gan-Or et al., 2015), but it is un-
known if either the GBA or VPS35 proteins are altered in




This study was approved by the University of NSW Human
Research Ethics Advisory (#HC14046) and frozen brain tissue
obtained from institutionally approved autopsy collections
held by the Sydney Brain Bank, the Tokyo Metropolitan
Brain Bank for Aging Research, the Queen Square Brain
Bank for Neurological Disorders, the University of Miami
Brain Endowment Bank and the New York Brain Bank at
Columbia University. Demographic information is provided
in Table 1. LRRK2 mutation cases were sourced worldwide
and matched for age, gender and post-mortem delay to idio-
pathic Parkinson’s disease cases, deﬁned according to Dickson
et al. (2009), and to unaffected control cases. The selection of
controls was based on no recorded clinical diagnosis of neuro-
logical or psychiatric symptoms, and the absence of CNS path-
ology at autopsy, including Lewy bodies, neuroﬁbrillary
tangles or neuritic plaque pathology. The 17 LRRK2 mutation
cases consisted of 12 with the G2019S mutation, and ﬁve with
the neighbouring I2020T mutation. All LRRK2 and idiopathic
Parkinson’s disease cases had diagnosed levodopa-responsive
Parkinson’s disease, and all had loss of pigmented neurons in
the substantia nigra at autopsy. Early-onset Parkinson’s disease
(younger than 50 years) was excluded. Except for Lewy path-
ology, described below, the changes in protein levels were con-
sistent for both LRRK2 mutations and were combined for
analysis as a single LRRK2 mutation group.
Protein extraction from brain tissue
Proteins were sequentially extracted from 100 mg of fresh-frozen
brain tissue based on their solubility in Tris-buffered saline (TBS)
and then sodium dodecyl sulphate (SDS) as described previously
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(Dzamko et al., 2017). This protein extraction method is com-
monly used to monitor the solubility change that occurs for
a-synuclein in Parkinson’s disease and allows for protein
levels to be examined in the context of a-synuclein pathology
(Zhou et al., 2011). The disease affected superior/middle frontal
cortex, which has Lewy pathology without neuronal loss late in
Parkinson’s disease, and the disease unaffected occipital cortex,
which is without neuronal loss or Lewy pathology in Parkinson’s
disease, were used for this study. Frozen substantia nigra, which
has a substantial loss of neurons at end-stage Parkinson’s disease,
was not available for the LRRK2 mutation cases.
Protein quantitation and
immunoblotting
The protein concentration of extracted lysates was determined
by bicinchoninic acid assay (Pierce) and made up to 1mg/ml in
1 lithium dodecyl sulphate sample buffer (Thermo Fisher).
Lysates were then separated on Novex 4-12% Tris Glycine
SDS-PAGE gels (Thermo Fisher), except for ATP13A2, which
was separated on 8% gels, and proteins transferred to nitro-
cellulose. Details of antibodies used for immunodetection are
provided in Supplementary Table 1. For all antibodies, except
Ser129 phosphorylated a-synuclein, membranes were blocked
with 5% skimmed milk in TBS buffer containing 0.1% Tween-
20 (Sigma), and incubated overnight as described previously
(Dzamko et al., 2017). For immunodetection of Ser129 phos-
phorylated a-synuclein, membranes were ﬁxed with 4% para-
formaldehyde and 0.1% glutaraldehyde (both from Sigma)
prior to blocking and antibody incubation as above (Sasaki
et al., 2015). Images were captured using a ChemiDocTM
MP imaging system using either horseradish peroxidase-conju-
gated secondary antibodies in conjunction with enhanced
chemiluminescence reagent (GE Healthcare), or Alexa Fluor
labelled secondary antibodies (Bio-Rad). The intensity of each
protein band was then quantiﬁed and expressed as arbitrary
units normalized to b-actin protein levels. Representative
cropped immunoblots are included in the ﬁgures with example
full-length immunoblots shown as Supplementary Fig. 1.
Statistics
All statistical analyses were performed using SPSS Statistics
software (IBM, Chicago, IL), with statistical signiﬁcance set at
P5 0.05. One-way ANOVA with Tukey post hoc test was
used to compare the demographic data across the groups,
and conﬁrmed no signiﬁcant differences in age or post-
mortem delay between groups. However, as we previously
identiﬁed a signiﬁcant relationship between LRRK2 protein
levels and post-mortem delay (Dzamko et al., 2017), post-
mortem delay was covaried for in all uni- or multivariate ana-
lyses used to determine differences in protein levels between
groups. Spearman correlations were performed to identify sig-
niﬁcant associations between different proteins, a-synuclein
pathology or demographic variables.
Results
Reduced LRRK2 protein and phos-
phorylation in LRRK2 mutation cases
The protein levels of LRRK2 and the phosphorylation of
LRRK2 at Ser910, Ser935 and Ser973 were ﬁrst examined
in the disease affected frontal cortex and compared across
the three groups. Consistent with our previous report
(Dzamko et al., 2017), LRRK2 was only found in the
SDS fraction and thus only this fraction was analysed.
Multivariate analysis revealed a signiﬁcant decrease (40%,
P5 0.05) in the levels of LRRK2 in the frontal cortex of
the LRRK2 mutation group compared to controls, whereas
the idiopathic Parkinson’s disease group was not signiﬁ-
cantly different from controls (Fig. 1A). After correction
to total levels of LRRK2, there was a 29%, 23% and
33% decrease in LRRK2 Ser910, Ser935 and Ser973 phos-
phorylation in the LRRK2 mutation cases compared to con-
trols (Fig. 1B–D). There was also a trend for reduced Ser935
phosphorylation in the idiopathic Parkinson’s disease cases,
whereas the other phosphorylation sites were not different
from controls. Post-mortem delay, which was included as a
covariate in the analyses, had no signiﬁcant effect
(P = 0.139). In the frontal cortex, no signiﬁcant correlations
were found between LRRK2 or measured demographic
variables (Supplementary Table 2), although the levels of
LRRK2 phosphorylation at Ser935 signiﬁcantly declined
Table 1 Demographic details
Control Idiopathic LRRK2 Parkinson’s disease
Combined G2019S I2020T
Sample size 14 13 17 12 5
Age at death, years 76  1.9 (63–89) 79  1.2 (72–85) 76  1.8 (58–85) 78  1.7 (65–85) 73  4.3 (58–81)
Gender (male/female) 8/6 8/5 6/11 4/8 2/3
Braak Lewy stage, /6 NA 5  0.2 (4.0–6.0) 3  0.5 (0.0–6.0) 5  0.2 (4.0–6.0) 0  0.2(0.0–1.0)
Symptom duration, years NA 15.62  1.33 (10.0–26.0) 18.54  2.39 (4.0–32.0) 17.00  3.28 (4.0–32.0) 21.00  3.45 (13.0–32.0)
Post-mortem delay, h 10.36  1.81 (2.0–23.0) 14.62  2.57 (5.0–32.0) 14.41  3.06 (2.0–45.0) 16.67  3.91 (4.0–45.0) 9.00  3.95 (2.0–24.0)
Storage time, years 9.93  0.85 (5.0–14.0) 5.46  0.54* (3.0–9.0) 12.88  1.59 (1.0–24.0) 13.83  1.68 (1.0–24.0) 10.60  3.71 (1.0–21.0)
Demographic data for the brain tissue cases used in this study are shown. Data are mean  SEM with the range shown parentheses. The LRRK2 G2019S and I2020T mutation groups
were combined into a single group for analysis. Demographic data for the individual mutation groups is shown for information. One-way ANOVA with the Tukey post hoc test was
used to measure differences across the three groups (control, idiopathic Parkinson’s disease and combined LRRK2 mutation Parkinson’s disease). *P5 0.05 compared to both
control and G2019S groups. NA = not applicable.
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with increasing symptom duration (rho = 0.400, P50.05,
Supplementary Table 2). We also examined levels of
LRRK2 in the disease-unaffected occipital cortex, which as
expected, was largely devoid of Ser129 phosphorylated
a-synuclein (Supplementary Fig. 2). In the unaffected occipi-
tal cortex, levels of LRRK2 were even more markedly
reduced (60% decrease, P5 0.001) compared to both
the idiopathic Parkinson’s disease and control groups
(Fig. 1E). After correction to levels of total LRRK2, there
was a trend for reduced Ser910 and Ser935 phosphoryl-
ation in the occipital cortex, however this did not reach
statistical signiﬁcance (Supplementary Fig. 3). Again, post-
mortem delay (P = 0.623) was used as a covariate in the
multivariate analysis. In the occipital cortex there was an
association between increased storage time and decreased
LRRK2 levels (rho = 0.336, P50.05, Supplementary
Table 2).
a-Synuclein pathology in LRRK2
mutation cases
In contrast to LRRK2, SDS-soluble a-synuclein phosphory-
lated at the pathological Ser129 residue was markedly
increased in idiopathic Parkinson’s disease frontal cortex
(5-fold increase, P5 0.01) compared to controls. However,
there was no signiﬁcant increase in a-synuclein Ser129 phos-
phorylation in the frontal cortex of the LRRK2 mutation
cases (Fig. 1F), despite similar symptom duration. This is
likely due to known differences in a-synuclein deposition
in the brains of subjects with different LRRK2 mutations
(Kalia et al., 2015), and indeed this was conﬁrmed when
the immunoblot analysis of phosphorylated a-synuclein
was correlated with the immunohistochemical analysis
of a-synuclein pathology based on Braak staging
(rho = 0.434, P5 0.05, Supplementary Fig. 4). When the
mutation group was considered as a whole, Braak Lewy
stage was signiﬁcantly reduced in the LRRK2 mutation
cases (Table 1); however, this was substantially driven by
the LRRK2 I2020T cases, in which Lewy bodies were not
detected. When the LRRK2 I2020T cases were excluded and
only the LRRK2 G2019S cases considered, the Braak Lewy
stage was similar between LRRK2 mutation and idiopathic
Parkinson’s disease cases (Table 1). Levels of Ser129 phos-
phorylated a-synuclein did not correlate with levels of
LRRK2 or LRRK2 phosphorylation in the cohorts
(Supplementary Table 2).
Reduced soluble GBA in idiopathic
Parkinson’s disease and LRRK2
mutation cases
As LRRK2 has been implicated in lysosomal function, we
investigated if Parkinson’s disease implicated lysosomal
proteins were altered in the LRRK2-mutation cases. In par-
ticular, we measured levels of GBA, along with levels of the
cation transporting ATPase 13A2 (ATP13A2), cathepsin D
(CatD) and lysosome-associated membrane protein 2A
(LAMP2A). For both idiopathic Parkinson’s disease and
the LRRK2 mutation cases, GBA was decreased in the
TBS fraction by 24% and 52%, respectively in the affected
frontal cortex, whereas in the SDS fraction it was not sig-
niﬁcantly different (Fig. 2A and B). Levels of GBA did not
associate with levels of LRRK2, Braak Lewy stage or stor-
age time; however, there was a signiﬁcant correlation of
TBS-soluble GBA with symptom duration (Supplementary
Table 3). LAMP2A and ATP13A2 were present in the SDS-
soluble fraction and a non-signiﬁcant trend for decreased
LAMP2A of20% was observed in the frontal cortex for
both idiopathic Parkinson’s disease and the LRRK2 muta-
tion cases compared to controls (Fig. 2C). There were no
signiﬁcant differences between the groups for levels of
ATP13A2 in the frontal cortex (Supplementary Fig. 5).
CatD was present in both the TBS and SDS soluble frac-
tions but was not signiﬁcantly different across the three
groups (Supplementary Fig. 5). Post-mortem delay was
included as a covariate in all analysis, but only for CatD
did post-mortem delay have a signiﬁcant effect on protein
levels (P5 0.01). The TBS-soluble fraction of CatD, but
not the other lysosomal proteins (Supplementary Table 3),
was also negatively correlated with storage time
(rho = 0.542, P5 0.001), indicating decreasing levels of
TBS CatD with increased storage (Supplementary Fig. 6).
Levels of TBS CatD, however, did correlate with levels
of phosphorylated a-synuclein (rho = 0.387, P50.01,
Fig. 2D), while LAMP2A (rho = 0.304, P5 0.05,
Fig. 2E) and ATP13A2 (rho = 0.331, P5 0.05, Fig. 2F)
correlated with levels of LRRK2 in the frontal cortex
(Supplementary Table 3). In the unaffected occipital
cortex there was no change in the levels of TBS soluble
GBA (Fig. 2G); however, LAMP2A was signiﬁcantly
reduced in the LRRK2 mutation cases (Fig. 2H). The
levels of LAMP2A did not correlate with LRRK2 in this
brain region.
Reduced Tris-buffered saline-soluble
VPS35 and reduced MPR300 in
LRRK2 mutation cases
LRRK2 has been linked to retromer function so we also
investigated levels of the key retromer proteins VPS35, and
the cation-independent mannose-6-phosphate receptor
(MPR300, encoded by IGF2R). Similar to GBA, levels of
TBS-soluble VPS35 were decreased in both idiopathic
Parkinson’s disease and the LRRK2 mutation cases in the
affected frontal cortex, by 32% and 50%, respectively,
whereas in the SDS fraction VPS35 levels were not signiﬁ-
cantly different (Fig. 3A and B). Post-mortem delay was
included as a covariate in the analysis but had no signiﬁ-
cant effect (P = 0.290). There was no association of VPS35
with storage time, LRRK2 levels or Braak Lewy stage
(Supplementary Table 4); however, there was a signiﬁcant
negative correlation between TBS and SDS-soluble VPS35
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(rho = 0.328, P50.05, Fig. 3C), indicating a change in
solubility. In the unaffected occipital cortex, the TBS frac-
tion of VPS35 was again signiﬁcantly reduced in both
Parkinson’s disease groups (Fig. 3D). Levels of MPR300,
which were detected only in the SDS fraction, showed a
38% decrease in the frontal cortex in the mutation cases
compared to controls and a signiﬁcant 77% reduction com-
pared to the idiopathic Parkinson’s disease group
(P5 0.05, Fig. 3E). Post-mortem delay, which was
included as a covariate in the univariate analysis, again
had no signiﬁcant effect (P = 0.188). There was no associ-
ation between MPR300 levels and storage time
(Supplementary Table 4); however, there was a signiﬁcant
correlation between levels of MPR300 and LRRK2
(rho = 0.392, P5 0.01, Fig. 3F). MPR300 was also
reduced in the occipital cortex of the mutation cases
Figure 1 Reduced LRRK2 levels in post-mortem brain with LRRK2 mutations. Multivariate analysis covarying for post-mortem delay
was used to assess changes in protein levels of leucine-rich repeat kinase 2 (LRRK2) in the frontal cortex (A), as well as the levels of LRRK2
phosphorylation on Ser910, Ser935 and Ser973 in frontal cortex (B–D) and levels of LRRK2 in occipital cortex (E) of controls (n = 14), idiopathic
Parkinson’s disease (iPD, n = 13) and LRRK2-associated Parkinson’s disease cases (n = 17). Levels of a-synuclein phosphorylated at Ser129 were
also measured in the frontal cortex (F). The LRRK2 mutation cohort consisted of cases with the G2019S mutation (green filled triangles) and the
I2020T mutation (upturned green unfilled triangles). P-values indicate whether or not there was a significant effect of Parkinson’s disease in the
multivariate analysis. Subsequent post hoc analysis was used to identify significantly different groups with *P5 0.05 and **P5 0.01 compared to
controls and +P5 0.05 and + + +P5 0.001 compared to the idiopathic Parkinson’s disease group. Individual data points are shown on the graph
as well as mean  standard error of the mean (SEM). Representative immunoblots are shown with uncropped examples available in the
Supplementary material. LRRK2 immunoblots were normalized to b-actin and values expressed as the per cent of control cases, which were set at
100%. Phosphorylated proteins were corrected to the levels of the corresponding total protein.
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Figure 2 Reduced TBS-soluble GBA levels in post-mortem brain with LRRK2 mutations. Multivariate analysis covarying for post-
mortem delay was used to assess changes in protein levels of GBA, ATP13A2, cathepsin D (CatD) and lysosome-associated membrane protein 2A
(LAMP2A) in controls (n = 14), idiopathic Parkinson’s disease (iPD, n = 13) and LRRK2-associated Parkinson’s disease cases (n = 17). (A and B)
TBS and SDS soluble levels of GBA in the frontal cortex. (C) Levels of LAMP2A in the frontal cortex. (D) Spearman analysis revealed a significant
correlation between levels of phosphorylated a-synuclein and TBS-soluble CatD, as well as significant correlations between LRRK2 and LAMP2A
(E), and LRRK2 and ATP13A2 (F). (G) Levels of TBS soluble GBA in the occipital cortex. (H) Levels of LAMP2A in the occipital cortex. The
LRRK2 mutation cohort consisted of cases with the G2019S mutation (green filled triangles) and the I2020T mutation (upturned green unfilled
triangles). P-values indicate a significant effect of Parkinson’s disease in the multivariate analysis. Subsequent post hoc analysis was used to identify
significantly different groups with *P5 0.05 compared to controls and +P5 0.05 compared to the idiopathic Parkinson’s disease cases. Individual
data points are shown on the graph as well as mean  SEM. Representative immunoblots are shown with uncropped examples available in the
Supplementary material. Immunoblots were normalized to b-actin and values expressed as the per cent of control cases, which were set at 100%.
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Figure 3 Reduced TBS-soluble VPS35 and reduced MPR300 in LRRK2 mutation cases. Multivariate analysis covarying for post-
mortem delay was used to assess changes in protein levels of VPS35 and MPR300 in controls (n = 14), idiopathic Parkinson’s disease (iPD, n = 13)
and LRRK2-associated Parkinson’s disease cases (n = 17). (A and B) Levels of TBS and SDS soluble VPS35 in the frontal cortex. (C) Spearman
analysis revealed a significant negative correlation between the levels of TBS- and SDS-soluble VPS35. (D) Levels of TBS-soluble VPS35 in the
occipital cortex. (E) Levels of MPR300 in the frontal cortex. (F) Spearman analysis revealed a significant correlation between the levels of MPR300
and LRRK2 in the frontal cortex. (G) Levels of MPR300 in the occipital cortex. (H) Spearman analysis revealed a significant correlation between
the levels of MPR300 and LRRK2 in the occipital cortex. The LRRK2 mutation cohort consisted of cases with the G2019S mutation (green filled
triangles) and the I2020T mutation (upturned green unfilled triangles). P-values indicate a significant effect of Parkinson’s disease in the univariate
analysis. Subsequent post hoc analysis was used to identify significantly different groups with *P5 0.05, **P5 0.01 compared to controls and
+P5 0.05 compared to the idiopathic Parkinson’s disease cases. Individual data points are shown on the graph as well as mean  SEM.
Representative immunoblots are shown with uncropped examples available in the Supplementary material. Immunoblots were normalized to
b-actin and values expressed as the per cent of control cases, which were set at 100%.
LRRK2 and retromer in Parkinson’s disease brain BRAIN 2017: Page 7 of 10 | 7
Downloaded from https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awx344/4741389
by University College London user
on 10 January 2018
compared to the control group (60%, P5 0.01, Fig. 3G)
and was again signiﬁcantly associated with levels of
LRRK2 (rho = 0.561, P50.001, Fig. 3H).
Discussion
Missense mutations in LRRK2 predispose to Parkinson’s
disease. In particular, pathogenic LRRK2 mutations in-
crease the enzymes kinase activity and there is accumulat-
ing evidence that the increased kinase activity mediates
LRRK2 pathobiology. Moreover, potent and selective in-
hibitors of LRRK2 kinase activity are in advanced stages
of development. There is now much interest in determining
whether such compounds could be used therapeutically for
LRRK2 mutation carriers. An important part of this pro-
cess is to understand levels of LRRK2 in human biospeci-
mens. Characterized post-mortem brain tissue from
symptomatic LRRK2 mutation carriers is extremely rare.
Our study investigates 17 Parkinson’s disease cases with
LRRK2 mutations, which to the best of our knowledge is
the majority of known and characterized cases worldwide,
with available frozen tissue samples. The LRRK2 mutation
cases had typical features, particularly the lack of
Lewy pathology in I2020T cases (Kalia et al., 2015). We
have used immunoblotting to measure LRRK2 and
other Parkinson’s disease-implicated proteins in cortical
brain tissue from these LRRK2 mutation carriers, and
have compared the protein levels to both idiopathic
Parkinson’s disease cases and neurologically normal
controls.
Previously, we have mapped the expression of LRRK2
protein in post-mortem idiopathic Parkinson’s disease
brain and in preclinical Parkinson’s disease cases with re-
stricted Lewy bodies (Dzamko et al., 2017). We showed
that LRRK2 protein was increased in the preclinical
cases, and then it decreased back to the same levels as
controls in a symptom duration-dependent manner. In the
current study, levels of LRRK2 were again similar between
control and idiopathic Parkinson’s disease, however, the
levels were reduced in the Parkinson’s disease cases with
LRRK2 mutations. Reduced LRRK2 was found in both the
frontal and occipital cortex and was not associated with
Lewy pathology. This suggests that reduced LRRK2 is
either a result of the pathogenic mutations, or potential
caveats associated with post-mortem brain studies. In
regard to the latter, cases were matched for age, gender
and post-mortem delay. All Parkinson’s disease cases also
had similar symptom durations. However, the idiopathic
Parkinson’s disease cases had been in freezer storage for
less time compared to the control and LRRK2 mutation
cases. Longer storage time was associated with lower
LRRK2 levels, at least in the occipital cortex. As the stor-
age time was similar between control and LRRK2 mutation
cases, it seems unlikely that this variable would completely
explain the decreased LRRK2 levels in the mutation cases,
albeit, increased storage time may have intensiﬁed the
magnitude of the results. We would recommend to others
using these rare LRRK2 mutation tissue samples to con-
sider the freezer storage time when matching affected and
control groups.
Reduced endogenous LRRK2 levels in association with
pathogenic LRRK2 mutations has not been routinely
observed. A number of studies have investigated the expres-
sion of LRRK2 in primary human ﬁbroblasts from
Parkinson’s disease cases and controls, and reported similar
levels of LRRK2 protein, albeit with very small sample sizes
and a diverse selection of antibodies (Devine et al., 2011;
Papkovskaia et al., 2012; Garcia-Miralles et al., 2015;
Smith et al., 2016). LRRK2 G2019S knock-in mice also
have similar levels of LRRK2 protein (Garcia-Miralles
et al., 2015). Difﬁculty in detecting LRRK2, particularly
in ﬁxed brain tissues has, however, made an assessment
of LRRK2 levels in post-mortem brain and human neural
cell cultures challenging. One study has reported a trend for
decreased LRRK2 mRNA in the cortex of LRRK2 G2019S
brain tissue (Sharma et al., 2011) and these cases are also
included in the current study. It is also reported that
LRRK2 inhibitors can destabilize LRRK2 and reduce pro-
tein levels (Lobbestael et al., 2016), suggesting a dynamic
interaction between LRRK2 enzyme activity and its protein
levels. If LRRK2 protein is reduced in the brain of patho-
genic LRRK2 mutation carriers, this would reduce the pool
of LRRK2 that can be actively targeted with inhibitor ther-
apy, especially with advancing disease progression at end-
stage disease. It may be important to determine if LRRK2
mutation carriers have an earlier increase in LRRK2
protein levels, similar to the early increase reported for
idiopathic Parkinson’s disease brain (Dzamko et al.,
2017). Novel radioligands for LRRK2 may make such stu-
dies possible in the future (Malik et al., 2017). Moreover, it
will be important to determine the relationship between
LRRK2 protein and LRRK2 kinase activity, studies that
could potentially be achieved by measuring phosphoryl-
ation levels of recently described LRRK2 substrates, such
as the Rab GTPases (Steger et al., 2016), when suitable
techniques become available.
As previously identiﬁed in idiopathic Parkinson’s disease
(Murphy et al., 2014), there was a reduction in soluble
GBA levels in Parkinson’s disease cases with LRRK2
mutations. GBA is a lysosomal enzyme required for gly-
colipid metabolism, with homozygous GBA mutations
producing a lysosomal storage disorder while heterozy-
gous GBA mutations are a risk factor for Parkinson’s
disease (Siebert et al., 2014). Reduced GBA function
is associated with elevated a-synuclein (Murphy et al.,
2014), but not all Parkinson’s disease cases with LRRK2
mutations have elevated a-synuclein, for example the
I2020T cases in the present study. This suggests an alter-
nate mechanism for reduced GBA and LRRK2 is likely in
these cases. In this regard, levels of LRRK2 in the frontal
cortex did correlate with two other lysosomal proteins,
LAMP2A and ATP13A2. In particular, LAMP2A has
been reported to be decreased in Parkinson’s disease
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(Murphy et al., 2015), including in cases with LRRK2
G2019S mutations (Henry et al., 2015). Moreover,
LAMP2A contributes to LRRK2 turnover through chap-
erone-mediated autophagy, although the G2019S muta-
tion is thought to render LRRK2 a poorer substrate for
degradation via this pathway (Orenstein et al., 2013).
Like LRRK2, missense mutations in VPS35 are patho-
genic for autosomal dominant Parkinson’s disease, which
is largely indistinguishable from idiopathic Parkinson’s
disease (Vilarino-Guell et al., 2011; Zimprich et al., 2011;
Struhal et al., 2014; Williams et al., 2017). In Drosophila,
LRRK2 and VPS35 have been functionally linked and
suggested to converge on the same biological pathway of
intraneuronal lysosomal/Golgi sorting to mediate neurode-
generation (MacLeod et al., 2013). Indeed, overexpression
of VPS35 can rescue the neurodegenerative phenotype
induced in Drosophila by either the LRRK2 G2019S mu-
tation (MacLeod et al., 2013) or the LRRK2 I2020T mu-
tation (Linhart et al., 2014), strongly suggesting an
interplay between these two important Parkinson’s disease
proteins. Our new data further support this concept as we
observed an apparent solubility shift in VPS35, with a re-
duction in TBS-soluble protein and an associated increase
in the SDS-soluble VPS35, particularly in the LRRK2 mu-
tation cases. This change in solubility was independent of
Lewy pathology. Such a shift could result from impaired
localization and may be indicative of retromer or lysosomal
dysfunction. VPS35 deﬁciency or mutation impairs endoso-
mal to Golgi retrieval of LAMP2A, which could impact on
the levels of LRRK2 as described above (Orenstein et al.,
2013). It should be noted that VPS35 levels have previously
been reported to be similar to controls in both idiopathic
Parkinson’s disease and LRRK2 G2019S post-mortem
brains (Tsika et al., 2014). In this prior study, brain protein
was extracted using only a single buffer, in contrast to our
current study that performed the sequential TBS, SDS
extraction commonly used to measure the accumulation
of pathogenic a-synuclein in Parkinson’s disease brain
(Zhou et al., 2011). Using this method, we observed
reduced TBS-soluble VPS35 with increased SDS-soluble
VPS35, consistent with the reported no net change in
total VPS35 levels. This does, however, indicate a change
in VPS35 associations likely to reﬂect retromer dysfunction.
Indeed, the retromer cargo protein, MPR300, was reduced
in the LRRK2 mutation cases, which can occur through
increased lysosomal degradation or extracellular secretion
when the protein is no longer trafﬁcked properly (Matrone
et al., 2016). Moreover, reduced levels of MPR300 were
associated with reduced levels of LRRK2. Therefore, it may
be important to model and understand the dynamic
relationship between LRRK2 and retromer, particularly in
regard to whether retromer dysfunction contributes to the
conversion of asymptomatic LRRK2 mutation carriers to
Parkinson’s disease.
The study of these Parkinson’s disease cases with LRRK2
mutation has provided important novel information.
Despite differences in the dysregulation of a-synuclein
between the G2019S versus the I2020T LRRK2 mutations,
similar reductions in the levels of LRRK2, GBA and the
retromer cargo protein MPR300 were observed, as well
as a shift in the solubility of VPS35. The reductions in
these measures were more marked in Parkinson’s disease
cases with LRRK2 mutations compared to those observed
in idiopathic Parkinson’s disease, which had more marked
increases in phosphorylated a-synuclein compared with the
LRRK2 mutation cases. The severity of these protein def-
icits were related to each other, suggesting the involvement
of related intracellular pathways. These data suggest that
LRRK2 mutation carriers have more substantial retromer
dysfunction compared with idiopathic Parkinson’s disease,
and that such dysfunction does not necessarily cause the
aggregation of a-synuclein.
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